This article is more than 5 years old. Information may no longer be current.

Zimmer Biomet acquires CD Diagnostics

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Zimmer Biomet Holdings Inc. announced it has acquired CD Diagnostics, according to a company press release. The financial terms of the transaction were not disclosed.

Initially partnered with CD Diagnostics in 2012 to co-develop and market diagnostics in the field of musculoskeletal health care, the release noted Zimmer Biomet successfully marketed the Synovasure Periprosthetic Joint Infection test. The test was designed and validated for the diagnosis of periprosthetic joint infection.

“Our acquisition of CD Diagnostics cements our leadership and competitive advantage in musculoskeletal diagnostics, strengthens our Signature Solutions offering and advances our mission to provide comprehensive musculoskeletal health care,” Dan Williamson, group president of joint reconstruction for Zimmer Biomet, said in the release.

He added, “We are excited to team up with CD Diagnostics to accelerate the pace of innovation in musculoskeletal diagnostics, ramp up adoption of testing into standard protocols and arm surgeons with critical data to inform diagnosis, staging, treatment and recovery.”

Reference:

www.prnewswire.com/news-releases/zimmer-biomet-strengthens-musculoskeletal-diagnostic-offering-with-acquisition-of-cd-diagnostics-300313291.html